Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,553 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07164976RecruitingPhase 1/Phase 2
Ribociclib for advanced HR+ HER2- breast cancer
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
NagoyaAges 18 years+ - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
Berkeley, CaliforniaAges 18 years+ - NCT06497010RecruitingEarly Phase 1
Personalized mRNA cancer vaccine for advanced solid tumors
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
Guiyang, China/GuizhouAges 18–75 - NCT06954558RecruitingPhase 1
GK01 for advanced solid tumors that are hard to treat
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
TianjinAges 18–70 - NCT07162038RecruitingPhase 1
CAR-T cells plus half-matched stem cell transplant for high-risk blood cancer
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
Bethesda, MarylandAges 18–75 - NCT07156136RecruitingPhase 1
Study of a new drug IMC-P115C for advanced PRAME-positive cancers
This trial tests an experimental drug, IMC-P115C, for people with advanced cancers that have a specific marker called PRAME and a genetic type HLA-A*02:01. It may be an option if other treatments have stopped working or caused side effects.
AdelaideAges 18 years+ - NCT07154316RecruitingPhase 2
Short radiation plus drugs for MSS rectal cancer
This trial tests a shorter course of radiation therapy followed by a combination of chemotherapy, immunotherapy, and a pain-relief medication, compared to the standard approach. It is for people with a certain type of rectal cancer that has not spread.
Fuzhou, FujianAges 18–75 - NCT07151118Recruiting
Blood test for advanced biliary tract cancer
This study uses a simple blood test (ctDNA) to learn more about the genetic makeup of advanced biliary tract cancers. It may help researchers understand how these cancers respond to treatment, and it doesn't involve any extra drugs or procedures—just blood draws.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07152678RecruitingPhase 2
Brachytherapy with radiation and immunotherapy for esophageal cancer
This trial tests combining brachytherapy (a type of internal radiation) with immunotherapy (nivolumab) for people with advanced esophageal cancer that has not fully responded to initial chemoradiation. The goal is to see if this targeted approach can improve outcomes.
Huwei, Yunlin CountyAges 18–85 - NCT06945718Recruiting
Green dye test for gastric cancer surgery
This trial tests whether a green dye called indocyanine green can help surgeons find and remove more lymph nodes during laparoscopic surgery for advanced stomach cancer. It may improve the chances of removing all cancer.
Fuzhou, FujianAges 18–75 - NCT07127822RecruitingPhase 2
Testing a new immunotherapy combo for MSI-H gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Shijiazhuang, HebeiAges 18 years+ - NCT06784765Recruiting
Preventive PIPAC for advanced stomach cancer
This trial tests if a special type of chemotherapy delivered as a mist during surgery (PIPAC) can help prevent the spread of stomach cancer. It is for people with advanced but not yet metastatic stomach cancer who have not had prior treatment.
AstanaAges 18 years+ - NCT07117630RecruitingPhase 2
A new drug combo for advanced breast cancer after standard treatment
This trial tests a new drug combination for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after standard treatments like CDK4/6 inhibitors and hormone therapy. It aims to see if the combination can help when other options have stopped working.
ShanghaiAges 18 years+ - NCT07125391RecruitingPhase 2
Chemo plus propranolol before surgery for advanced ovarian cancer
This trial tests adding propranolol (a heart medication) to standard chemotherapy before surgery for advanced high-grade serous ovarian cancer. The goal is to see if this combination helps shrink tumors more effectively.
Hefei, AnhuiAges 18–75 - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07120529Recruiting
Comparing two types of hysterectomy for early cervical cancer
This study looks at two ways to remove the uterus and cervix for early-stage cervical cancer: minimally invasive surgery (like laparoscopic or robotic) versus open surgery (traditional large incision). It checks whether the less invasive approach works just as well in terms of survival and keeping the cancer from coming back.
BialystokAges 18–85 - NCT07106814RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy (Meta10-TIL) made from your own immune cells that were trained to attack cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including cervical, liver, lung, breast, ovarian, head and neck, or colorectal cancer.
Hefei, AnhuiAges 19–70 - NCT07108309RecruitingPhase 2
Study of BCD-236 with chemotherapy for recurrent triple-negative breast cancer
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
BrestAges 18–74 - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months - NCT07106762RecruitingPhase 2/Phase 3
Study of new targeted drug vs chemo for bladder cancer
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Gilbert, ArizonaAges 18 years+ - NCT07114315RecruitingPhase 2
Study of AK130 plus AK112 for advanced pancreatic cancer
This trial tests a combination of two investigational drugs, AK130 and AK112, for people with advanced pancreatic cancer. It may be an option if you have had 1 or 2 prior treatments and are still relatively healthy.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07113275RecruitingPhase 3
Short versus long radiation schedule for advanced rectal cancer
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Wuhan, HubeiAges 18–75 - NCT07108127RecruitingPhase 2
Targeted drugs plus chemo for HER2-positive rectal cancer
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
BeijingAges 18 years+ - NCT07106034RecruitingPhase 2
Testing a new combo therapy for advanced colorectal cancer
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,553 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.